Study of REM-422 in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB
mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)